The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy

被引:67
|
作者
Khan, Nadia A. [1 ]
Hemmelgarn, Brenda [2 ]
Herman, Robert J. [3 ]
Rabkin, Simon W. [4 ]
McAlister, Finlay A. [5 ]
Bell, Chaim M. [6 ,8 ]
Touyz, Rhian M. [7 ]
Padwal, Raj [5 ]
Leiter, Lawrence A. [8 ]
Mahon, Jeff L. [9 ]
Hill, Michael D. [10 ]
Larochelle, Pierre [11 ]
Feldman, Ross D. [12 ,13 ,14 ]
Schiffrin, Ernesto L. [15 ]
Campbell, Norman R. C. [16 ,17 ,18 ]
Arnold, Malcolm O. [19 ]
Moe, Gordon [8 ]
Campbell, Tavis S. [20 ]
Milot, Alain [21 ]
Stone, James A. [22 ]
Jones, Charlotte [23 ]
Ogilvie, Richard I. [24 ]
Hamet, Pavel [25 ]
Fodor, George [26 ]
Carruthers, George [27 ]
Burns, Kevin D. [28 ]
Ruzicka, Marcel [28 ]
deChamplain, Jacques [29 ]
Pylypchuk, George [30 ,31 ]
Petrella, Robert [32 ]
Boulanger, Jean-Martin [10 ]
Trudeau, Luc [33 ]
Hegele, Robert A. [34 ]
Woo, Vincent [35 ]
McFarlane, Phil [36 ]
Vallee, Michel [37 ]
Howlett, Jonathan [38 ]
Katzmarzyk, Peter [39 ]
Tobe, Sheldon [36 ]
Lewanczuk, Richard Z. [40 ]
机构
[1] Univ British Columbia, Div Gen Internal Med, Vancouver, BC V5Z 1M9, Canada
[2] Univ Calgary, Div Nephrol, Calgary, AB, Canada
[3] Univ Calgary, Div Gen Internal Med, Calgary, AB, Canada
[4] Univ British Columbia, Div Cardiol, Vancouver, BC V5Z 1M9, Canada
[5] Univ Alberta, Div Gen Internal Med, Edmonton, AB, Canada
[6] Univ Toronto, Dept Med & Hlth Policy, Toronto, ON, Canada
[7] Univ Ottawa, Ottawa Hlth Res Ctr, Ottawa, ON, Canada
[8] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[9] Univ Western Ontario, Dept Med & Endocrinol, London, ON, Canada
[10] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[11] Univ Montreal, Inst Rech Clin Montreal, Montreal, PQ, Canada
[12] Univ Western Ontario, Robarts Res Inst, London, ON, Canada
[13] Univ Western Ontario, Dept Med, London, ON, Canada
[14] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada
[15] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Dept Med, Montreal, PQ, Canada
[16] Univ Calgary, Dept Med, Calgary, AB, Canada
[17] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[18] Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada
[19] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada
[20] Univ Calgary, Dept Physiol, Calgary, AB, Canada
[21] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada
[22] Univ Calgary, Div Cardiol, Calgary, AB T2N 1N4, Canada
[23] Univ Calgary, Div Endocrinol, Dept Med, Calgary, AB T2N 1N4, Canada
[24] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[25] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada
[26] Univ Ottawa, Inst Heart, Prevent & Rehabil Ctr, Ottawa, ON, Canada
[27] United Arab Emirates Univ, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[28] Univ Ottawa, Div Nephrol, Ottawa, ON, Canada
[29] Univ Montreal, Clin Res Inst Montreal, Montreal, PQ, Canada
[30] Univ Saskatchewan, Div Nephrol, Saskatoon, SK, Canada
[31] York Univ, Dept Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada
[32] Univ Western Ontario, Dept Family Med, London, ON, Canada
[33] McGill Univ, Dept Med, Montreal, PQ, Canada
[34] Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada
[35] Univ Manitoba, Div Endocrinol & Metab, Winnipeg, MB, Canada
[36] Univ Toronto, Div Nephrol, Toronto, ON, Canada
[37] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada
[38] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[39] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
[40] Univ Alberta, Div Endocrinol, Edmonton, AB, Canada
关键词
antiltypertensive drugs; blood pressure; guidelines; high blood pressure; hypertension; lifestyle interventions;
D O I
10.1016/S0828-282X(08)70620-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To Update the evidence-based recommendations for the prevention and management of hypertension in adults. OPTIONS AND OUTCOMES: For lifestyle and pharmacological interventions, evidence was preferentially reviewed from randomized controlled trials and systematic reviews of trials. Changes in cardiovascular morbidity and mortality were the primary outcomes of interest. However, for lifestyle interventions, blood pressure lowering was accepted as a primary outcome given the lack of long-term morbidity and mortality data in this field. Progression of kidney dysfunction was also accepted as a clinically relevant primary Outcome among patients with chronic kidney disease. EVIDENCE: A Cochrane collaboration librarian conducted an independent MEDLINE search from 2006 to August 2007 to update the 2007 recommendations. To identify additional published studies, reference lists were reviewed and experts were contacted. All relevant articles were reviewed and appraised independently by content and methodological experts Using prespecified levels of evidence. RECOMMENDATIONS: For lifestyle modifications to prevent and treat hypertension, restrict dietary sodium intake to less than 100 mmol/day (and 65 mmol/day to 100 mmol/day in hypertensive patients); perform 30 min to 60 min of aerobic exercise four to seven clays per week; maintain a healthy body weight (body mass index 18.5 kg/m(2) to 24.9 kg/m(2)) and waist circumference (smaller than 102 cm for trien and smaller than 88 cm for women); limit alcohol consumption to no more than 14 Units per week in men or nine units per week in women; follow a diet that is reduced in saturated far and cholesterol, and one that emphasizes fruits, vegetables and low-fat dairy Products, dietary and soluble fibre, whole grains and protein from plant sources; and consider stress management in selected individuals With hypertension. For the pharmacological management of hypertension, treatment thresholds and targets should be predicated oil by the patients global atherosclerotic risk, target organ damage and comorbid conditions. Blood pressure should be decreased to lower than 140/90 mmHg in all patients, and to lower than 130/80 mmHg in those with diabetes mellitus or chronic kidney disease. Most patients will require more than one agent to achieve these target blood pressures. For adults without compelling indications for other agents, initial therapy should include thiazide diuretics. Other agents appropriate for first-line therapy for diastolic and/or systolic hypertension include angiotensin-converting enzyme (ACE) inhibitors (in nonblack patients), long-acting calcium channel blockers (CCBs), angiotensin receptor antagonists (ARBs) or beta-blockers (in those younger than 60 years of age). A combination of two first-line agents may also be considered for initial treatment of hypertension if systolic blood pressure is 20 mmHg above target or if diastolic blood pressure is 10 mmHg above target. Other agents appropriate for first-line therapy for isolated systolic hypertension include long-acting dihydropyridine CCBs or ARBs. In patients with angina, recent myocardial infarction or heart failure, beta-blockers and ACE inhibitors are recommended as first-line therapy; in patients with cerebrovascular disease, an ACE inhibitor/diuretic combination is preferred; in patients with protein-uric nondiabetic chronic kidney disease, ACE inhibitors are recommended; and in patients with diabetes mellitus, ACE inhibitors or ARBs (or, in patients without albuminuria, thiazides or dihydropyridine CCBs) are appropriate first-line therapies. All hypertensive patients with dyslipidemia should be treated using the thresholds, targets and agents outlined in the Canadian cardiovascular Society position statement (recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease). Selected high-risk patients with hypertension but who do not achieve thresholds for statin therapy according to the position paper should nonetheless receive statin therapy. Once blood pressure is controlled, acetylsalicylic acid therapy should be considered. VALIDATION: All recommendations were graded according to strength of the evidence and voted on by the 57 members of the Canadian Hypertension Education Program Evidence-Based Recommendations Task Force. All recommendations reported here achieved at least 95% consensus, sus. These guidelines will continue to be updated annually.
引用
收藏
页码:465 / 475
页数:11
相关论文
共 50 条
  • [21] The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk
    Hemmelgarn, BR
    McAlister, FA
    Grover, S
    Myers, MG
    McKay, DW
    Bolli, P
    Abbott, C
    Schiffrin, EL
    Honos, G
    Burgess, E
    Mann, K
    Wilson, T
    Penner, B
    Tremblay, G
    Milot, A
    Chockalingam, A
    Touyz, RM
    Tobe, SW
    CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (07) : 573 - 581
  • [22] The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk
    Hemmelgarn, BR
    Zarnke, KB
    Campbell, NR
    Feldman, RD
    McKay, DW
    McAlister, FA
    Khan, N
    Schiffrin, EL
    Myers, MG
    Bolli, P
    Honos, G
    Lebel, M
    Levine, M
    Padwal, R
    CANADIAN JOURNAL OF CARDIOLOGY, 2004, 20 (01) : 31 - 40
  • [23] The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1-blood pressure measurement, diagnosis and assessment of risk
    Padwal, Raj S.
    Hemmelgarn, Brenda R.
    Khan, Nadia A.
    Grover, Steven
    McKay, Donald W.
    Wilson, Thomas
    Penner, Brian
    Burgess, Ellen
    McAlister, Finlay A.
    Bolli, Peter
    Hill, Michael D.
    Mahon, Jeff
    Myers, Martin G.
    Abbott, Carl
    Schiffrin, Ernesto L.
    Honos, George
    Mann, Karen
    Tremblay, Guy
    Milot, Alain
    Cloutier, Lyne
    Chockalingam, Arun
    Rabkin, Simon W.
    Dawes, Martin
    Touyz, Rhian M.
    Bell, Chaim
    Burns, Kevin D.
    Ruzicka, Marcel
    Campbell, Norman R. C.
    Vallee, Michel
    Prasad, Ramesh
    Lebel, Marcel
    Tobe, Sheldon W.
    CANADIAN JOURNAL OF CARDIOLOGY, 2009, 25 (05) : 279 - 286
  • [24] Management of Hypertension in People with Diabetes Mellitus: Translating the 2012 Canadian Hypertension Education Program Recommendations into Practice
    Makowsky, Mark
    Prebtani, Ally P. H.
    Gelfer, Mark
    Manohar, Advaita
    Jones, Charlotte
    CANADIAN JOURNAL OF DIABETES, 2012, 36 (06) : 345 - 353
  • [25] Diagnosing hypertension Evidence supporting the 2015 recommendations of the Canadian Hypertension Education Program
    Gelfer, Mark
    Dawes, Martin
    Kaczorowski, Janusz
    Padwal, Raj
    Cloutier, Lyne
    CANADIAN FAMILY PHYSICIAN, 2015, 61 (11) : 957 - 961
  • [26] New algorithm for the diagnosis of hypertension - Canadian hypertension education program recommendations (2005)
    Myers, MG
    Tobe, SW
    McKay, DW
    Bolli, P
    Hemmelgarn, BR
    McAlister, FA
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (10) : 1369 - 1374
  • [27] Applying the 2005 Canadian Hypertension Education Program recommendations: 5. Therapy for patients with hypertension and diabetes mellitus
    Tobe, S
    McAlister, FA
    Leiter, L
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (10) : 1154 - 1157
  • [28] Canadian Hypertension Education Program: The evolution of hypertension management guidelines in Canada
    Feldman, Ross D.
    Campbell, Norman R.
    Wyard, Katherine
    CANADIAN JOURNAL OF CARDIOLOGY, 2008, 24 (06) : 477 - 481
  • [29] Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations
    Touyz, Rhian M.
    CANADIAN JOURNAL OF CARDIOLOGY, 2006, 22 (07) : 565 - 571